Thymosin Alpha-1 Description
Thymosin Alpha-1 (Tα1, or TA1, also known as thymalfasin or Zadaxin) is a 28-amino acid acetylated peptide with a molecular weight of 3108 Da. Originally isolated from the thymus gland. It is produced endogenously and functions as an immunomodulator, enhancing T-cell-mediated immune responses. Approved in over 35 countries; in the United States, approved by the FDA under the Orphan Drug Designation program.
With aging, the thymus undergoes involution, leading to immune senescence—a gradual decline in thymic function and hormone production that reduces immune function, particularly in the T-cells.
Tα1 supports cellular enhancement and immune modulation by preventing cellular senescence and enhancing crosstalk between innate and adaptive immune responses. As a master peptide (alongside TB4), it counters the inflammatory state of senescent cells; Tα1 acts directly as a senolytic agent and senomodulator, while TB4 functions as a senomodulator.
Tα1 is pleiotropic: it enhances innate immunity when needed and suppresses it when not. As a thymic peptide, it restores immune homeostasis and is influenced by physiological and pathological conditions (e.g., viral infections, cancer, immunodeficiency, vaccination, and immunosenescence). It functions as a multifunctional protein, depending on the host's inflammatory or immune-dysfunctional state, modulating the immune system by augmenting T-cell function.
Molecular Level Mechanism of Action
Tα1 acts via multiple immunomodulatory pathways:
- T-Cell Modulation: Binds to Toll-like receptors (TLR2 and TLR9) on dendritic cells, promoting activation and maturation of T-cells, increasing CD4+/CD8+ ratios, and stimulating cytokine production (e.g., IL-2, IFN-γ). Affects thymocytes by stimulating their differentiation or converting them to active T-cells. Balances TH1/TH2 arms of immunity through augmentation of T-lymphocyte function, including modulation of interleukin-2 (IL-2), stimulation of interferon-γ (IFN-γ) production, induction of T-lymphocytes and NK cells, and stimulation of thymopoiesis.
- NK Cell and Cytokine Enhancement: Boosts natural killer (NK) cell activity and cytokine-mediated responses, reversing T-cell exhaustion.
- Macrophage transition from M1 into M2 phase. M1 macrophages promote colitis primarily by secreting pro-inflammatory cytokines, including IL-6, IL-1β, and interferon (IFN)-γ, leading to type 1 responses and acute inflammation. M2 macrophages express large amounts of IL-10 and help activate type 2 responses that promote tissue repair.
- Anti-Proliferative Effects: Directly inhibits tumor cell proliferation or induces apoptosis in infected cells.
- Immune Balance: Regulates innate and adaptive immunity, alleviating immunosuppression in conditions like sepsis or pancreatitis.
- Upregulates MHC class I expression in antigen-presenting cells.
- Downregulates activity of terminal deoxynucleotidyl transferase (TdT) in TdT+ thymocytes, aiding thymocyte maturation.
- Stimulates activity of indoleamine-2,3-dioxygenase (IDO), leading to an increase in FOXP3+ IL-10-producing regulatory T-cells and inhibition of cytokine production.
Applications
Cell-Enhancing Applications
- Promotes T and B- cell differentiation and maturation (in vivo and in vitro data), Treg, Breg differentiation
- Decreases T-cell apoptosis.
- Improves TH1 responses.
- Balances TH1/TH2.
- Activates indoleamine 2,3-dioxygenase enzyme; dampens immunity.
- Enhances dendritic cells.
- Enhances antibody responses.
- Blocks steroid-induced apoptosis of thymocytes.
- Has antitumor effects.
- Provides protection against oxidative damage.
·
·
Latest Studies (2023–2025)
- Severe Acute Pancreatitis (June 2025): Tα1 alleviated inflammation, prevented infections, and regulated immunity by increasing CD4+ T-cell counts and the CD4+/CD8+ ratio in patients (PubMed: 40599771).
- Sepsis Trial (January 2025): The TESTS trial found no evidence that Tα1 reduces 28-day mortality in adults with sepsis, though it may modulate immune markers (BMJ: bmj-2024-082583).
- Aging and Immunosenescence (2025): Preclinical/clinical data have shown that Tα1 improves vaccine responses in the elderly and mitigates age-related immune decline; the hybrid drug Refnot (Tα1 fusion) enhanced efficacy (MDPI: IJMS 26/23/11470).
- COVID-19 Immune Modulation (2023–2024): Tα1 reduced cytokine storms, increased lymphocytes, reversed T-cell exhaustion in severe cases, and enhanced vaccine immunogenicity in elderly/immunocompromised patients (ScienceDirect: S1567576923013085; Oxford Academic: ofid/ofaa588).
- Aortic Dissection Surgery (May 2025): PANDA II trial protocol assesses Tα1's effects on immune response and organ function post-surgery (Future Cardiology).
Potential clinical settings:
- In ALS, Thymosin Alpha 1 modulates immune responses by enhancing T-cell activation and restoring immune homeostasis, potentially reducing neuroinflammation in ALS through suppression of excessive T-cell activation and promotion of regulatory T-cells. At the molecular level, it interacts with immune cells, including dendritic cells, via TLR signalling, thereby balancing immune activation to mitigate ALS-associated immune dysregulation. It supports mitochondrial function by improving cellular energy balance and reducing oxidative stress, as evidenced in models in which it enhances mitochondrial efficiency. Indirectly influencing the gut microbiota through immune modulation may help normalize microbiome composition disrupted in ALS. Overall, these mechanisms could slow ALS progression by alleviating immune-mediated neuronal damage and restoring metabolic stability.
- TA1 in LADA Diabetes decreases the Gada, ICA; IA2; ZnT8 level
Properties
- Synthetic thymic peptide
- 28 amino acids
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.
- MW = 3108.28
- Modulates innate immunity
- Pleiotropic
Related research context:
→Thymosin Alpha-1 – High Purity Research Peptide
Broader research perspective
This compound is frequently examined within experimental models focused on maintaining cellular balance, metabolic regulation, redox homeostasis, and long-term functional stability. For an integrated overview of these research pathways, see:
→ Cellular Homeostasis & Health Maintenance Research